Picture [LSUS] – The Business Web Portal 600x60px
Document › Details

Agilent Technologies Inc.. (3/14/16). "Press Release: Agilent Technologies Publishes Overview of Best Practices for Breast Cancer Diagnosis". Carpinteria, CA.

Organisation Organisation Dako Pathology Solutions division (Agilent)
Products Product cancer test
  Product 2 companion diagnostic test
Persons Person Pedersen, Hans Christian (Agilent 201603 Head of Companion Diagnostics + IHC reagents)
  Person 2 Wadsworth-Hansen, Victoria (Agilent 201506 Director Global Business Public Relations)

Agilent Technologies Inc. (NYSE: A), a worldwide provider of cancer diagnostics through its Dako Pathology Solutions division, today announced that it has published "Breast Cancer Diagnosis: Past, Present and Future," a white paper on the use of immunohistochemistry in diagnosing and treating breast cancer.

The white paper was made available at a gathering of the United States and Canadian Academy of Pathology under way this week in Seattle.

"Agilent is committed to providing industry-leading educational resources to our customers, and we are particularly excited about this publication," said Hans Christian Pedersen, head of Companion Diagnostics and IHC reagents, Global Marketing, Agilent. "It provides pathologists with a comprehensive resource for the diagnosis of breast cancers."

An overview of best practices, the paper was written by doctors Ping Tang and David G. Hicks of the University of Rochester in New York and Christine Desmedt of the Jules Bordet Institute in Brussels.

The 51-page paper reviews how the understanding of breast cancer has evolved and how researchers have established clinically meaningful biomarkers and ancillary tests. It also discusses the potential (and possible pitfalls) of applying these biomarkers in diagnosing breast cancer and planning treatment.

"By uniting morphological, immunohistochemical and molecular methods, pathologists can provide a comprehensive diagnosis that supports individualized therapy for breast cancer patients," said Dr. Ping Tang, one of the co-authors from Rochester. "By covering useful antibodies and molecular tests in one comprehensive source, we think this article will be a valuable educational resource for breast pathologists."

About Agilent Technologies and Dako

Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics and applied chemical markets, is the premier laboratory partner for a better world. Agilent works with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. The company generated revenues of $4.04 billion in fiscal 2015 and employs about 12,000 people worldwide.

In 2012, Agilent acquired Dako, a well-known provider of reagents, instruments, software and expertise. Agilent's Dako pathology solutions help pathologists make accurate diagnoses and determine the most effective treatment for cancer patients.

Information about Agilent is available at, and information about Agilent's Dako pathology solutions products is available here.

# # #


Victoria Wadsworth-Hansen
+1 408 553 2005

Record changed: 2017-07-02


Picture [LSA] – The Business Web Portal 650x89px

More documents for Agilent (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BIO-Europe 2019 Partnering Report BEU2019 650x80px

» top